Jim Simons Exelixis, Inc. Transaction History

Renaissance Technologies LLC

$63.4 Billion
Q4 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Exelixis, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 15,295,865 shares of EXEL stock, worth $537 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares

15,295,865

Previous 15,359,916 0.42%

Holding current value

$537 Million

Previous $399 Million 27.79%

% of portfolio

0.8%

Previous 0.63%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$25.39 - $36.46 $1.63 Million - $2.34 Million	-64,051 Reduced 0.42%	15,295,865 $509 Million
Q3 2024 Nov 13, 2024	BUY	$21.96 - $27.6 $4.32 Million - $5.43 Million	196,850 Added 1.3%	15,359,916 $399 Million
Q2 2024 Aug 09, 2024	BUY	$20.34 - $23.73 $1.25 Million - $1.46 Million	61,350 Added 0.41%	15,163,066 $341 Million
Q1 2024 May 13, 2024	SELL	$20.17 - $23.93 $10.4 Million - $12.3 Million	-514,000 Reduced 3.29%	15,101,716 $358 Million
Q4 2023 Feb 13, 2024	BUY	$19.25 - $24.13 $7.68 Million - $9.62 Million	398,800 Added 2.62%	15,615,716 $375 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $10.8 Million - $12.9 Million	569,327 Added 3.89%	15,216,916 $332 Million
Q2 2023 Aug 11, 2023	SELL	$18.17 - $20.48 $11.5 Million - $12.9 Million	-631,800 Reduced 4.13%	14,647,589 $280 Million
Q1 2023 May 12, 2023	BUY	$16.3 - $19.41 $5.19 Million - $6.18 Million	318,300 Added 2.13%	15,279,389 $297 Million
Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $16 Million - $18.6 Million	-1,069,755 Reduced 6.67%	14,961,089 $240 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $27.5 Million - $39 Million	-1,753,093 Reduced 9.86%	16,030,844 $251 Million
Q2 2022 Aug 12, 2022	BUY	$17.44 - $23.16 $16.1 Million - $21.3 Million	921,659 Added 5.47%	17,783,937 $370 Million
Q1 2022 May 13, 2022	SELL	$17.03 - $22.67 $4.06 Million - $5.41 Million	-238,500 Reduced 1.39%	16,862,278 $382 Million
Q4 2021 Feb 11, 2022	SELL	$15.84 - $21.88 $7.08 Million - $9.77 Million	-446,723 Reduced 2.55%	17,100,778 $313 Million
Q3 2021 Nov 12, 2021	SELL	$16.3 - $21.14 $8.72 Million - $11.3 Million	-535,000 Reduced 2.96%	17,547,501 $371 Million
Q2 2021 Aug 13, 2021	SELL	$17.95 - $25.56 $9.88 Million - $14.1 Million	-550,300 Reduced 2.95%	18,082,501 $329 Million
Q1 2021 May 13, 2021	SELL	$20.53 - $25.22 $62.6 Million - $76.9 Million	-3,049,850 Reduced 14.07%	18,632,801 $421 Million
Q4 2020 Feb 10, 2021	SELL	$18.39 - $24.8 $18.1 Million - $24.4 Million	-982,959 Reduced 4.34%	21,682,651 $435 Million
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $7.05 Million - $9.19 Million	-341,300 Reduced 1.48%	22,665,610 $554 Million
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $48.3 Million - $80.5 Million	2,935,850 Added 14.63%	23,006,910 $546 Million
Q1 2020 May 14, 2020	BUY	$14.46 - $21.8 $30.6 Million - $46.2 Million	2,117,134 Added 11.79%	20,071,060 $346 Million
Q4 2019 Feb 13, 2020	BUY	$15.15 - $18.89 $47 Million - $58.6 Million	3,104,330 Added 20.91%	17,953,926 $316 Million
Q3 2019 Nov 13, 2019	BUY	$17.68 - $22.65 $24.7 Million - $31.6 Million	1,395,123 Added 10.37%	14,849,596 $263 Million
Q2 2019 Aug 12, 2019	BUY	$18.93 - $24.75 $73.6 Million - $96.3 Million	3,889,200 Added 40.66%	13,454,473 $288 Million
Q1 2019 May 14, 2019	BUY	$19.6 - $24.76 $71.5 Million - $90.3 Million	3,645,546 Added 61.58%	9,565,273 $228 Million
Q4 2018 Feb 13, 2019	BUY	$13.65 - $21.8 $80.8 Million - $129 Million	5,919,727 New	5,919,727 $116 Million

Others Institutions Holding EXEL

# of Institutions

564

Shares Held

251M

Call Options Held

1.45M

Put Options Held

1.13M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.3B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account